Research in Immune Tolerance in Transplantation

TolerogenixX is a clinical-stage biopharmaceutical company based in Heidelberg, Germany, specializing in the development of personalized cell therapies to induce permanent immune tolerance. The company's proprietary MIC (Modified Immune Cells) technology involves the ex vivo modification of donor or patient cells to suppress unwanted immune responses without the need for lifelong immunosuppression. Its lead program, MIC-Tx, is currently in Phase 2 clinical trials for kidney transplant recipients, aiming to prevent organ rejection and reduce the side effects associated with traditional immunosuppressive drugs. TolerogenixX is also expanding its platform to address autoimmune diseases, such as Systemic Lupus Erythematosus and Multiple Sclerosis.